NXGL NEXGEL, INC.
Listings ·
Every 20 shares of common stock will combine into one share at 12:01 a.m. Eastern Time on October 12, 2026. The common stock will keep its Nasdaq Capital Market listing under NXGL with a new CUSIP.
Brian Kieser became interim chief executive on August 21, 2026, as Adam Levy left the role. A special committee will review non-core assets, liquidity and the company's long-term strategic direction.
The July 23, 2026 agreement sets a $375,000 base salary, EBITDA-linked bonus tiers and an option grant of 160,000 shares at $0.647 per share.
The unsecured note converts at $0.60 a share and goes to Brian J. Kieser, a new director who runs Sequence LifeScience. Sequence bought $5,500,000 of notes in an earlier April financing.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $11.4 million | $8.7 million |
| Research and development | $2,000 | $78,000 |
| Net income (loss) | -$3.0 million | -$3.3 million |
| Cash from operations | -$1.3 million | -$3.9 million |
| Cash and equivalents | $1.8 million |
Our latest story on this, dated Oct 7, 2026: "NexGel sets a 1-for-20 reverse stock split effective October 12, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 11, 2026: "NexGel issues $1,000,000 convertible note to new director Brian J. Kieser". The story links the filing or release it is based on. Read the story.
NEXGEL, INC. trades under the ticker NXGL on NASDAQ.
NEXGEL, INC. is listed on NASDAQ.
Our directory records NEXGEL, INC. under United States.
aibio.space lists NEXGEL, INC. among 2,820 public biotech companies and publishes its news here as stories appear.
$11.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
NEXGEL, INC. reported a net loss of $3.0 million for the fiscal year ended Dec 31, 2025, and used $1.3 million of cash in operations, per its annual report to the SEC.
$2,000 in the fiscal year ended Dec 31, 2025, per its annual report.
$1.7 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on NEXGEL, INC., dated Oct 7, 2026: "NexGel sets a 1-for-20 reverse stock split effective October 12, 2026". Every 20 shares of common stock will combine into one share at 12:01 a.m. Eastern Time on October 12, 2026. The common stock will keep its Nasdaq Capital Market listing under NXGL with a new CUSIP. Source.
Press Follow on this page to add NEXGEL, INC. to your Following list, or subscribe to the aibio.space newsletter. We have published 4 stories naming NEXGEL, INC. so far, in Company Updates, Debt Financing, Listings.
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio